The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%. ・Ardelyx’s net ...

Purple said that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future ...

Over the past generation, advances in treating common cancers—breast, lung, melanoma, and gastrointestinal (GI)—have improved ...

Safety: ARV-102 was generally well tolerated at single doses up to 200 mg and multiple daily doses up to 80 mg, with no discontinuations due to adverse events (AEs) or serious adverse events (SAEs) ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, ...

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of ...

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

Shanghai Zhimeng Biopharma Inc. ( 'Zhimeng') announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially ...